XOMA
XOMA Royalty CorpPrice & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Assets added to portfolio | 22 | Full year 2025 | — |
| Cash receipts | $50.5M | Full year 2025 | — |
| Cash receipts from royalties and commercial payments | $3.2M | Q4 2025 | — |
| Dividends paid on XOMA Royalty Perpetual Preferred stocks | $5.5M | Full year 2025 | — |
| Milestone payments | $3.3M | Q4 2025 | — |
| Milestone payments and fees | $16.9M | Full year 2025 | — |
| Non-dilutive capital accumulated from company acquisitions | $11.7M | Since the beginning of 2025 | — |
| Potential milestone payments from company acquisitions | $1.1B | Since the beginning of 2025 | — |
| Royalties and commercial payments | $33.6M | Full year 2025 | — |
| Shares repurchased | 648,048 | Full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
XOMA
this stock
XOMA Royalty Corp
|
$539.26M | +61.7% | +498.7% | 27.4 | 7.2% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| XOMA | +1.9% | +3.1% | +43.7% | +1.2% | +61.7% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +0.5% | +4.4% | +35.7% | +1.5% | +52.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.